microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 20:1043-1048, 2002 8. Lanza G, Gafa R, Santini A, et al: Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J Clin Oncol 24:2359-2367, 2006 9. Kakar S, Aksoy S, Burgart LJ, et al: Mucinous carcinoma of the colon: Correlation of loss of mismatch repair enzymes with clinicopathologic features and survival. Mod Pathol 17:696-700, 2004 10. Popat S, Hubner R, Houlston RS: Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23:609-618, 2005 11. Elsaleh H, Joseph D, Grieu F, et al: Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355: 1745-1750, 2000 12. Sargent D, Marsoni S, Monges G, et al: Defective mismatch repair as a predictive marker for lack of efficacy of FU-based adjuvant therapy in colon cancer. J Clin Oncol 28:3219-3227, 2010 13. Ribic CM, Sargent DJ, Moore MJ, et al: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247-257, 2003 14. QUASAR Collaborative Group, Gray R, Barnwell J, et al: Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study. Lancet 370:2020-2029, 2007 15. Roth AD, Tejpar S, Yan P, et al: Correlation of molecular markers in colon cancer with stage-specific prognosis: Results of the translational study on the PETACC3 – EORTC 40993-SAKK 60-00 trial. Presented at the ASCO GI Cancer Symposium, San Francisco, CA, January 15-17, 2009 (abstr 288) 16. Kerr D, Gray R, Quirke P, et al: A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study. J Clin Oncol 27:15s, 2009 (suppl; abstr 4000)